This article is more than 5 years old. Information may no longer be current.
EOS receives FDA approval for THA planning software
Click Here to Manage Email Alerts
EOS Imaging recently announced the FDA has approved hipEOS, the company’s new 3-D planning software for total hip arthroplasty procedures.
Designed with the intent to improve preoperative planning, hipEOS allows surgeons to test everything from hip implant selection to positioning in functional, weight-bearing 3-D based on the anatomical data specific to each patient. These data stem from the company’s stereo-radiographic 2-D/3-D imaging and represent the first instance of a software portfolio offered with the EOS imaging system, according to a company press release.
This improvement in planning via hipEOS is believed to aid surgeons in the accuracy of the restoration they anticipate following THA.
HipEOS is scheduled to be launched by the company at the American Academy of Orthopedic Surgeons Annual Meeting in March, according to the release.
“HipEOS is the first step of our strategy to fully utilize EOS’ unique stereo-radiographic 2-D/3-D patient data in software tools that will help surgeons plan and execute precise surgical and nonsurgical treatments,” Marie Meynadier, CEO of EOS Imaging, said in the release. “We are very happy to have been granted market approval in the U.S. and to extend this offering, which has received a very positive feedback at the French SOFCOT launch in November, to our U.S. users and future users.”
Reference: www. eos-imaging.com.